Insider transactions

EDGAR

Rapid Micro Biosystems, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
14 transactions, 277,205 shares
Sum of shares × price per share: 1,138,003.3033

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 59

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-24 Filed 2026-07-24Kollender Richard S Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Class A Common Stock
Acquired (A)1,6810.75
1,260.75

Derived: shares × price per share. Exact value 1260.75.

131,999Direct (D) No— Open filing 0001415666-26-000008 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-24Kollender Richard S Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Class A Common Stock
Acquired (A)1,8270.75
1,370.25

Derived: shares × price per share. Exact value 1370.25.

133,826Direct (D) No— Open filing 0001415666-26-000008 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-24Kollender Richard S Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (1,681) — exercise price 0.75
Disposed (D)1,6810—0Direct (D) No
F1
  • F1 The option is fully vested and exercisable.
Open filing 0001415666-26-000008 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-24Kollender Richard S Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (1,827) — exercise price 0.75
Disposed (D)1,8270—0Direct (D) No
F1
  • F1 The option is fully vested and exercisable.
Open filing 0001415666-26-000008 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-24Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Class A Common Stock
Acquired (A)1,4020.75
1,051.5

Derived: shares × price per share. Exact value 1051.50.

1,191,973Direct (D) No— Open filing 0001853904-26-000020 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-24Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (1,402) — exercise price 0.75
Disposed (D)1,4020—0Direct (D) No
F1
  • F1 The option is fully vested and exercisable.
Open filing 0001853904-26-000020 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)12,7871.955
24,998.585

Derived: shares × price per share. Exact value 24998.585.

1,190,571Direct (D) No
F1, F2
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F2 Includes 7,936 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on March 13, 2026.
Open filing 0001853904-26-000017 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series A Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 1.955
Acquired (A)12,7870—12,787Direct (D) No
F1, F3
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F3 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001853904-26-000017 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series B Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 2.34
Acquired (A)12,7870—12,787Direct (D) No
F1, F3
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F3 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001853904-26-000017 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)12,7871.955
24,998.585

Derived: shares × price per share. Exact value 24998.585.

568,981Direct (D) No
F1
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
Open filing 0001289733-26-000014 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series A Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 1.955
Acquired (A)12,7870—12,787Direct (D) No
F1, F2
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F2 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001289733-26-000014 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series B Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 2.34
Acquired (A)12,7870—12,787Direct (D) No
F1, F2
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F2 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001289733-26-000014 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Malloy Kirk Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)12,7871.955
24,998.585

Derived: shares × price per share. Exact value 24998.585.

60,687Direct (D) No
F1
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
Open filing 0001326794-26-000007 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Malloy Kirk Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series A Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 1.955
Acquired (A)12,7870—12,787Direct (D) No
F1, F3
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F3 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001326794-26-000007 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Malloy Kirk Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series B Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 2.34
Acquired (A)12,7870—12,787Direct (D) No
F1, F3
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F3 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001326794-26-000007 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02PEI MELINDA LITHERLAND Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)12,7871.955
24,998.585

Derived: shares × price per share. Exact value 24998.585.

100,687Direct (D) No
F1
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
Open filing 0001703469-26-000010 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02PEI MELINDA LITHERLAND Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series A Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 1.955
Acquired (A)12,7870—12,787Direct (D) No
F1, F2
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F2 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001703469-26-000010 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02PEI MELINDA LITHERLAND Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series B Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 2.34
Acquired (A)12,7870—12,787Direct (D) No
F1, F2
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F2 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001703469-26-000010 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02LOWENSTEIN INESE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)12,7871.955
24,998.585

Derived: shares × price per share. Exact value 24998.585.

70,687Direct (D) No
F1
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
Open filing 0001900476-26-000008 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02LOWENSTEIN INESE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series A Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 1.955
Acquired (A)12,7870—12,787Direct (D) No
F1, F2
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F2 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001900476-26-000008 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02LOWENSTEIN INESE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Series B Warrant (right to buy) — underlying Class A Common Stock (12,787) — exercise price 2.34
Acquired (A)12,7870—12,787Direct (D) No
F1, F2
  • F1 On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
  • F2 The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Open filing 0001900476-26-000008 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26PEI MELINDA LITHERLAND Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)19,3000—87,900Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001703469-26-000007 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26PEI MELINDA LITHERLAND Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (38,700) — exercise price 2.07
Acquired (A)38,7000—38,700Direct (D) No
F2
  • F2 The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001703469-26-000007 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26Bika Dafni Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)19,3000—19,300Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0002070373-26-000003 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26Bika Dafni Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (38,700) — exercise price 2.07
Acquired (A)38,7000—38,700Direct (D) No
F2
  • F2 The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0002070373-26-000003 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26Malloy Kirk Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)19,3000—47,900Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001326794-26-000003 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26Malloy Kirk Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (38,700) — exercise price 2.07
Acquired (A)38,7000—38,700Direct (D) No
F3
  • F3 The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001326794-26-000003 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26LOWENSTEIN INESE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)19,3000—57,900Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001900476-26-000005 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26LOWENSTEIN INESE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (38,700) — exercise price 2.07
Acquired (A)38,7000—38,700Direct (D) No
F2
  • F2 The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001900476-26-000005 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26Kollender Richard S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)19,3000—130,318Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001415666-26-000005 Read from the filing’s XML Dispute this row
2026-05-21 Filed 2026-05-26Kollender Richard S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (38,700) — exercise price 2.07
Acquired (A)38,7000—38,700Direct (D) No
F2
  • F2 The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Open filing 0001415666-26-000005 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences Partners, LP 10% ownerBain Capital Life Sciences Fund, L.P. 10% ownerBCIP Life Sciences Associates, LP 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Pre-Funded Warrant (right to buy) — underlying Class A Common Stock (1,463,000) — exercise price 0.01
Acquired (A)1,463,000——1,463,000Indirect (I) See footnotesNo
F1, F2, F3, F6
  • F1 On May 20, 2026, BCLS I Investco, LP (BCLS I Investco) purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.
  • F2 The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
  • F3 The Pre-Funded Warrant does not expire.
  • F6 Bain Capital Life Sciences Investors, LLC (BCLSI) is the general partner of each of BCLSP and BCLS I Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-237016 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences Partners, LP 10% ownerBain Capital Life Sciences Fund, L.P. 10% ownerBCIP Life Sciences Associates, LP 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Series A Warrant (right to buy) — underlying Class A Common Stock (1,463,000) — exercise price 1.955
Acquired (A)1,463,000——1,463,000Indirect (I) See footnotesNo
F1, F2, F6
  • F1 On May 20, 2026, BCLS I Investco, LP (BCLS I Investco) purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.
  • F2 The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
  • F6 Bain Capital Life Sciences Investors, LLC (BCLSI) is the general partner of each of BCLSP and BCLS I Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-237016 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences Partners, LP 10% ownerBain Capital Life Sciences Fund, L.P. 10% ownerBCIP Life Sciences Associates, LP 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Series B Warrant (right to buy) — underlying Class A Common Stock (1,463,000) — exercise price 2.34
Acquired (A)1,463,000——1,463,000Indirect (I) See footnotesNo
F1, F2, F6
  • F1 On May 20, 2026, BCLS I Investco, LP (BCLS I Investco) purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.
  • F2 The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
  • F6 Bain Capital Life Sciences Investors, LLC (BCLSI) is the general partner of each of BCLSP and BCLS I Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-237016 Read from the filing’s XML Dispute this row
2026-03-11 Filed 2026-03-12Wilson John J. Addington Officer: CHIEF OPERATING OFFICER
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)9,6034.3181
41,466.7143

Derived: shares × price per share. Exact value 41466.7143.

316,762Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001872301-26-000012 Read from the filing’s XML Dispute this row
2026-03-11 Filed 2026-03-12WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)7,4804.3181
32,299.388

Derived: shares × price per share. Exact value 32299.3880.

556,194Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001289733-26-000011 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-12Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)17,9224.1115
73,686.303

Derived: shares × price per share. Exact value 73686.3030.

1,169,848Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001853904-26-000013 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-02RICCIARDI NATALE S Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Class A Common Stock
Acquired (A)8420.75
631.5

Derived: shares × price per share. Exact value 631.50.

29,442Direct (D) No— Open filing 0001107158-26-000002 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-02RICCIARDI NATALE S Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (842) — exercise price 0.75
Disposed (D)8420.75
631.5

Derived: shares × price per share. Exact value 631.50.

0Direct (D) No
F1
  • F1 The option is fully vested and exercisable.
Open filing 0001107158-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-20WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)17,2543.923
67,687.442

Derived: shares × price per share. Exact value 67687.442.

563,674Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001289733-26-000008 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-20Wilson John J. Addington Officer: CHIEF OPERATING OFFICER
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)5,4033.923
21,195.969

Derived: shares × price per share. Exact value 21195.969.

326,365Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001872301-26-000009 Read from the filing’s XML Dispute this row
2026-02-19 Filed 2026-02-20Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)38,3273.8853
148,911.8931

Derived: shares × price per share. Exact value 148911.8931.

1,187,770Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001853904-26-000010 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)264,0000—1,226,097Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the grant date) and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date.
Open filing 0001380106-26-000013 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (528,000) — exercise price 4.20
Acquired (A)528,0000—528,000Direct (D) No
F2
  • F2 The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.
Open filing 0001380106-26-000013 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Wilson John J. Addington Officer: CHIEF OPERATING OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)74,0000—331,768Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the grant date) and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date.
Open filing 0001380106-26-000017 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Wilson John J. Addington Officer: CHIEF OPERATING OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (147,000) — exercise price 4.20
Acquired (A)147,0000—147,000Direct (D) No
F2
  • F2 The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.
Open filing 0001380106-26-000017 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)97,0000—580,928Direct (D) No
F1
  • F1 Grant of restricted stock units (RSUs) that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the grant date) and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date.
Open filing 0001380106-26-000015 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Class A Common Stock (193,000) — exercise price 4.20
Acquired (A)193,0000—193,000Direct (D) No
F2
  • F2 The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.
Open filing 0001380106-26-000015 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-10Spignesi Robert G. Jr. Director · Officer: PRESIDENT AND CEO
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)12,8403.7827
48,569.868

Derived: shares × price per share. Exact value 48569.8680.

962,097Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001853904-26-000004 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-10WIRTJES SEAN M Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Class A Common Stock
Disposed (D)6,0273.7827
22,798.3329

Derived: shares × price per share. Exact value 22798.3329.

483,928Direct (D) No
F1
  • F1 Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.
Open filing 0001289733-26-000004 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–39 of 39

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Bain Capital Life Sciences Investors, LLC 8,434,560 SH8,687,596 dollarsUnchanged Prior quarter: 8,434,560Open filing 0001193125-26-462089 Filed 2026-11-16 Dispute this row
ARMISTICE CAPITAL, LLC 2,017,963 SH2,078,502 dollarsLower by 1,310,037 Prior quarter: 3,328,000Open filing 0001315863-26-000784 Filed 2026-11-16 Dispute this row
ABG-WTT Global Life Science Capital Partners GP Ltd 1,848,296 SH1,903,745 dollarsUnchanged Prior quarter: 1,848,296Open filing 0001193125-26-463671 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 953,744 SH982,356 dollarsLower by 28,290 Prior quarter: 982,034Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
KHAZANAH NASIONAL BERHAD 566,905 SH583,912 dollarsUnchanged Prior quarter: 566,905Open filing 0000905148-26-004863 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager246,458 SH253,969 dollarsHigher by 18,417 Prior quarter: 228,041Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager239,987 SH247,187 dollarsHigher by 27,886 Prior quarter: 212,101Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
BlackRock, Inc. Partly reported under another manager196,894 SH202,801 dollarsHigher by 7,062 Prior quarter: 189,832Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 184,900 SH190,447 dollarsHigher by 74,416 Prior quarter: 110,484Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 183,034 SH188,525 dollarsLower by 53,565 Prior quarter: 236,599Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager182,361 SH187,832 dollarsHigher by 166,219 Prior quarter: 16,142Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Corient Private Wealth LP 173,719 SH178,931 dollarsNot in the prior quarter’s filings read Open filing 0001948780-26-000012 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager93,874 SH96,690 dollarsUnchanged Prior quarter: 93,874Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
GSA CAPITAL PARTNERS LLP 79,076 SH81 dollarsNot in the prior quarter’s filings read Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row
XTX Topco Ltd Partly reported under another manager65,036 SH66,987 dollarsLower by 14,691 Prior quarter: 79,727Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager63,506 SH65,559 dollarsLower by 40,686 Prior quarter: 104,192Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager60,005 SH60 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
Squarepoint Ops LLC Partly reported under another manager58,359 SH60,110 dollarsNot in the prior quarter’s filings read Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager49,069 SH50,541 dollarsNot in the prior quarter’s filings read Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Temasek Holdings (Private) Ltd Partly reported under another manager43,636 SH44,945 dollarsNot in the prior quarter’s filings read Open filing 0001021944-26-000015 Filed 2026-10-28 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager42,106 SH43,369 dollarsUnchanged Prior quarter: 42,106Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Pekin Hardy Strauss, Inc. 40,000 SH41,200 dollarsNot in the prior quarter’s filings read Open filing 0001020317-26-000005 Filed 2026-11-02 Dispute this row
FNY Investment Advisers, LLC 35,000 SH36 dollarsNot in the prior quarter’s filings read Open filing 0001742998-26-000005 Filed 2026-10-16 Dispute this row
MORGAN STANLEY Partly reported under another manager33,147 SH34,141 dollarsHigher by 5,560 Prior quarter: 27,587Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
AXQ CAPITAL, LP 15,796 SH16,270 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002583 Filed 2026-11-12 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager11,638 SH11,987 dollarsUnchanged Prior quarter: 11,638Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
Vanguard Global Advisers, LLC 11,630 SH11,979 dollarsUnchanged Prior quarter: 11,630Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager10,870 SH11,196 dollarsNot in the prior quarter’s filings read Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Wealth Analytics Partners, LLC 10,000 SH10,300 dollarsNot in the prior quarter’s filings read Open filing 0001214659-26-013040 Filed 2026-10-19 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager7,302 SH7,521 dollarsHigher by 5,402 Prior quarter: 1,900Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
DUPONT CAPITAL MANAGEMENT CORP 3,370 SH3,471 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-040602 Filed 2026-10-23 Dispute this row
UBS Group AG Partly reported under another manager2,753 SH2,836 dollarsLower by 3,854 Prior quarter: 6,607Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager724 SH782 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager295 SH318 dollarsLower by 14,005 Prior quarter: 14,300Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager204 SH0 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager109 SH118 dollarsUnchanged Prior quarter: 109Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
SBI Securities Co., Ltd. 30 SH31 dollarsHigher by 15 Prior quarter: 15Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
Caitong International Asset Management Co., Ltd 21 SH22 dollarsLower by 14 Prior quarter: 35Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
BARCLAYS PLC Partly reported under another manager2 SH2 dollarsLower by 335 Prior quarter: 337Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Evernest Financial Advisors, LLC 506,000 SH
  • Advent International, L.P. 379,794 SH
  • ESSEX INVESTMENT MANAGEMENT CO LLC 362,696 SH
  • SEI INVESTMENTS CO 66,869 SH
  • ALGERT GLOBAL LLC 38,307 SH
  • JANE STREET GROUP, LLC 25,931 SH
  • HRT FINANCIAL LP 23,093 SH
  • NANO CAP NEW MILLENNIUM GROWTH FUND L P 12,500 SH
  • Larson Financial Group LLC 8,395 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Longitude Capital Partners II, LLC Class A common stock, $0.01 par value per share3.31,514,24510/15/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-464016 Dispute this row
Longitude Venture Partners II, L.P. Class A common stock, $0.01 par value per share3.31,514,24510/15/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-464016 Dispute this row
Patrick G. Enright Class A common stock, $0.01 par value per share3.51,596,28010/15/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-464016 Dispute this row
Juliet Tammenoms Bakker Class A common stock, $0.01 par value per share3.51,579,87310/15/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-464016 Dispute this row
Armistice Capital, LLC Class A common stock, $0.01 par value per share7.293,328,000.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001172661-26-003614 Dispute this row
Steven Boyd Class A common stock, $0.01 par value per share7.293,328,000.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001172661-26-003614 Dispute this row
Bain Capital Life Sciences Fund, L.P. Class A Common Stock, par value $0.01 per share16.767,651,36906/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-350331 Dispute this row
BCIP Life Sciences Associates, LP Class A Common Stock, par value $0.01 per share1.72783,19106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-350331 Dispute this row
Longitude Capital Partners II, LLC Class A common stock, $0.01 par value per share8.63,529,24503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-227039 Dispute this row
Longitude Venture Partners II, L.P. Class A common stock, $0.01 par value per share8.63,529,24503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-227039 Dispute this row
Longitude Prime Partners, LLC Class A common stock, $0.01 par value per share0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-227039 Dispute this row
Longitude Prime Fund, L.P. Class A common stock, $0.01 par value per share0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-227039 Dispute this row
Patrick G. Enright Class A common stock, $0.01 par value per share8.63,529,24503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-227039 Dispute this row
Juliet Tammenoms Bakker Class A common stock, $0.01 par value per share8.63,529,24503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-227039 Dispute this row
Endeavour Medtech Growth II LP Common Stock, par value $0.015.72,257,09912/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-051663 Dispute this row
Endeavour Medtech Growth II Parallel LP Common Stock, par value $0.015.72,257,09912/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-051663 Dispute this row
Endeavour Medtech II GP Limited Common Stock, par value $0.015.72,257,09912/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-051663 Dispute this row
SPIGNESI ROBERT G JR Class A Common Stock, $0.01 par value per share6.32,647,256.0003/28/2024 Filed 2025-08-19SCHEDULE 13DOpen filing 0001380106-25-000185 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,598,888 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020224,461
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Rapid Micro Biosystems, Inc.